7-chloro-2-(1-methyl-1H-imidazol-2-yl)-thieno[3,2-b]pyridine | 225385-11-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 7-chloro-2-(1-methyl-1H-imidazol-2-yl)-thieno[3,2-b]pyridine
• 英文别名: 7-chloro-2-(1-methylimidazol-2-yl)thieno[3,2-b]pyridine
• CAS: 225385-11-5
• 化学式: C₁₁H₈ClN₃S
• 分子量: 249.724
• InChiKey: LJYQFQKUXOCPNI-UHFFFAOYSA-N

物化性质

• 沸点：
  442.6±55.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  59
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-chloro-2-(1-methyl-1H-imidazol-2-yl)-thieno[3,2-b]pyridine 生成 1-methyl-6-[2-(1-methyl-1H-imidazol-2-yl)-thieno[3,2-b]pyridin-7-yloxy]-1H-indole-3-carboxylic acid methylamide
  参考文献：
  名称：

  Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use

  摘要：

  这项发明涉及由公式I1表示的化合物，以及这些化合物的前药或代谢物，或这些化合物的药用可接受的盐或溶剂，所述前药和所述代谢物，其中Z、Y、R11和R14、R15、R16和R17如本文所定义。该发明还涉及含有公式I化合物的药物组合物，以及通过给哺乳动物施用公式I化合物来治疗过度增殖性疾病的方法。

  公开号：

  US20040009965A1
• 作为产物：
  描述：

  7-氯噻吩并[3,2-b]吡啶 在 正丁基锂 、 ammonium acetate 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 溶剂黄146 为溶剂， 反应 26.17h， 生成 7-chloro-2-(1-methyl-1H-imidazol-2-yl)-thieno[3,2-b]pyridine
  参考文献：
  名称：

  Development of a Scalable Synthesis to VEGFR Inhibitor AG-28262

  摘要：

  The synthesis of N,2-dimethyl-6-(2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)benzo[b]thiophene-3-carboxamide (1, AG-28262) on kilogram scale is described. Initial syntheses of key components 2 and 3 worked well on laboratory scale but had significant drawbacks for larger-scale manufacture. Therefore, new routes to these two key fragments were developed and demonstrated to synthesize kilogram quantities. Key steps involve a two-step thiophenol alkylation/cyclization protocol to synthesize 2 in a convergent manner. A difficult Pd-mediated coupling to produce 3 was replaced with a more scalable stepwise imidazole synthesis. Key rationale for the new routes are discussed.

  DOI：

  10.1021/op0502396

文献信息

• [EN] BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE<br/>[FR] DERIVES D'AMIDE HETEROARYLE BENZOCONDENSE DE THIENOPYRIDINES UTILISEES EN TANT QU'AGENTS THERAPEUTIQUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES D'UTILISATION ASSOCIES
  申请人：PFIZER

  公开号：WO2003106462A1

  公开（公告）日：2003-12-24

  The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

  该发明涉及由公式I表示的化合物，以及这些化合物的前药或代谢物，或者这些化合物的药用可接受的盐或溶剂化合物，所述前药和代谢物，其中Z、Y、R11和R14、R15、R16和R17如本文所定义。该发明还涉及含有公式I化合物的药物组合物，以及通过给予公式I化合物来治疗哺乳动物的增殖过度性疾病的方法。
• Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use
  申请人：——

  公开号：US20040019065A1

  公开（公告）日：2004-01-29

  The invention relates to compounds represented by the formula I 1 and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein X, R 1 and R 11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

  这项发明涉及由公式I表示的化合物，以及这些化合物的前药、药学上可接受的盐或溶剂，其中X、R1和R11如本文所定义。该发明还涉及含有公式I化合物的药物组合物，以及通过给予公式I化合物来治疗哺乳动物的过度增殖性疾病的方法。
• Inhibitors of VEGF receptor and HGF receptor signaling
  申请人：Saavedra Mario Oscar

  公开号：US20070004675A1

  公开（公告）日：2007-01-04

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

  该发明涉及抑制VEGF受体信号和HGF受体信号。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
• Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
  申请人：Pfizer Inc.

  公开号：US06492383B1

  公开（公告）日：2002-12-10

  The invention relates to compounds of the formulas 1 and 2 and to pharmaceutically acceptable salts and hydrates thereof, wherein X1, R1, R2 and R11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas 1 and 2 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formulas 1 and 2.

  本发明涉及式1和式2的化合物以及其药学上可接受的盐和溶剂合物，其中X1、R1、R2和R11如本文所定义。本发明还涉及包含式1和式2化合物的药物组合物，以及通过施用式1和式2的化合物治疗哺乳动物的过度增殖性疾病的方法。
• [EN] INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING<br/>[FR] INHIBITEURS DE SIGNALISATION DE RECEPTEUR DU FACTEUR DE CROISSANCE ENDOTHELIALE (VEGF) ET DE RECEPTEUR DE FACTEUR DE CROISSANCE DES HEPATOCYTES (HGF)
  申请人：METHYLGENE INC

  公开号：WO2006010264A1

  公开（公告）日：2006-02-02

  The invention relates to the inhibition of vascular endothelial growth factor (VEGF) receptor signaling and hepatocyte growth factor (HGF) receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

  该发明涉及抑制血管内皮生长因子（VEGF）受体信号和肝细胞生长因子（HGF）受体信号的方法。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和症状的组合物和方法。